Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas

Table 5

Patients baseline characteristics based on IL-15 ≥ 76.5 pg/mL versus IL-15 < 76.5 pg/mL.

Characteristics	IL-15 < 76.5 pg/mL (𝑛=25)	IL-15 ≥ 76.5 pg/mL (𝑛=25)	𝑃-value
Age at transplant, years: median (range)	62 (44–73)	54 (23–71)	.02
Gender			.2
Female	6	11
Male	19	14
Lymphoma type			.7
DLBCL	17	17
Mantle cell	5	5
T-cell	3	2
Follicular	0	1
Prognostic factors at diagnosis
Extranodal disease			.2
0	15	17
1	8	7
2	2	0
LDH (U/L), median (range)	222 (150–550)	200 (170–1515)	.5
Performance status			.1
0	12	19
1	12	5
2	1	1
Stage			.3
I	2	4
II	1	4
III	4	4
IV	18	13
IPI score
Age at transplant, years			.1
≥60	15	8
<60	10	17
Extranodal sites			.5
≥2	2	0
<2	23	25
LDH (U/L)			.3
Abnormal	13	8
Normal	12	17
Performance status			.9
≥2	1	1
<2	24	24
Stage			.2
I/II	3	8
III/IV	22	17
IPI index			.03
0	1	4
1	4	11
2	15	7
3	5	3
Disease status prior to transplant			.5
CR	6	9
PR	19	16
Infused CD34 cells × 10^6/kg; median (range)	5.17 (2.2–8.56)	4.4 (2.03–8.1)	.2
ALC-15 cells/𝜇L: median (range)	0.65 (0.02–1.91)	0.68 (0.1–4.5)	.2
ALC-15 cells/𝜇L			.2
≥500	15	20
<500	10	5
Infused A-ALC × 10^9 lymphocytes/kg: median (range)	0.55 (0.02–1.66)	0.63 (0.14–1.66)	.1
Infused A-ALC			.2
≥0.5 × 10^9 lymphocytes/kg	14	19
<0.5 ×10^9 lymphocytes/kg	11	6
Infused A-mono × 10^9 monocytes/kg: median (range)	0.57 (0.06–1.5)	0.65 (0.26–1.5)	.3
Mono-15 cells/𝜇L: median (range)	0.85 (0.02–2)	0.86 (0.06–4.5)	.8
NK-15 cells/𝜇L: median (range)	98 (10–744)	130 (12–999)	.8

A-ALC: autograft, absolute lymphocyte count; ALC-15: absolute lymphocyte count at day 15 post transplant; A-mono: autograft absolute monocyte count; CR: complete remission; DLBCL: diffuse large B-cell lymphoma; IPI: International prognostic index; LDH: lactate dehydrogenase; Mono-15: absolute monocyte count at day 15 post transplant; PR: partial remission; NK-15: absolute natural killer cell count at day 15 post transplant.